UPDATE 1-Roche buys BioImagene for $100 mln, boosts diagnostics

* Bolsters Roche in tissue-based cancer diagnostics

* Deal likely to close in the coming weeks

(Adds details, analyst comment, Roche stock price)

ZURICH, Aug 23 (BestGrowthStock) – Swiss drugmaker Roche Holding AG
(ROG.VX: ) is buying U.S-based BioImagene for some $100 million,
making another bolt-on acquisition to cement its dominant
position in tissue-based cancer diagnostics.

Diagnostics is gaining more importance in cancer treatment,
which is being increasingly dovetailed to the genetic profile of
patients. Roche is the world’s largest maker of cancer drugs.

“As part of the personalised healthcare approach,
pathologists are increasingly involved in generating information
with high impact on treatment decisions,” Daniel O’Day, COO at
Roche Diagnostics said in a statement.

BioImagene’s products create high-resolution, whole-slide
digital images from glass microscope slides. The privately held
group also provides the software to view, analyse and manage
tissue images using a computer.

“We view the bolt-on acquisition as a good complement to the
existing offering in tissues diagnostics, which is becoming
increasingly important and crucial for personalised therapy
options,” Kepler Capital Markets analyst Martin Voegtli said in
a note.

At 0903 GMT, Roche stock was little changed at 139.90 Swiss
francs, while the European healthcare index traded 0.6 percent
firmer. (.SXDP: )
(Reporting by Katie Reid; Editing by Louise Heavens)

UPDATE 1-Roche buys BioImagene for $100 mln, boosts diagnostics